Business Description
This fund puts the vast majority of its money into companies working to advance human health, particularly those developing new medical treatments using biological science. It follows established global industry standards to select which companies qualify, focusing on firms that use living cells to create therapies and potential cures for disease. Because the fund concentrates heavily in this single area of healthcare, it carries more risk than a broadly spread investment portfolio.
